

**PENGANA HARDING LOEVNER INTERNATIONAL FUND**

**DESCRIPTION**

An International Fund targeting superior risk-adjusted returns through investing in high-quality and durable growing companies at reasonable prices.

The Pengana Harding Loevner International Fund invests in high-quality, growing companies identified through fundamental research with a long-term, global perspective.

Pengana has appointed Harding Loevner to managed the Fund. Harding Loevner is a New Jersey-based global equity fund manager formed in 1989 with over US\$86billion in Assets under Management.

Harding Loevner' analysts search the world for companies that meet their high quality and durable growth criteria, conduct fundamental research, then value and rate their stocks to make them available to PMs for investment.

**PERFORMANCE TABLE**

NET PERFORMANCE FOR PERIODS ENDING 30 Apr 2025<sup>1</sup>


**Pengana Harding Loevner International Fund Class B**

The Class was established in 1 July 2015. From June 2021 Harding Loevner was appointed as the investment manager for the Fund.

	1M	1Y	2Y	3Y	Since Harding Loevner Appointed June 2021 <sup>1</sup>	5Y	Since Fund Inception July 2015 <sup>2</sup>	Since Strategy Inception November 1989 <sup>3</sup>
<b>Fund (APIR PCL0026AU)<sup>1,2</sup></b> Managed by Harding Loevner from June 2021	-1.0%	12.7%	15.5%	11.4%	5.7%	8.4%	9.5%	
<b>Current Strategy (Partial Simulation)<sup>4</sup></b> Harding Loevner Global Equity Strategy						9.6%	10.9%	9.4%
<b>Index<sup>5</sup></b>	-1.7%	13.5%	16.5%	14.2%	11.1%	13.6%	11.1%	7.5%

**PERFORMANCE CHART**

NET PERFORMANCE SINCE INCEPTION<sup>2</sup>



**TOP HOLDINGS (ALPHABETICALLY)**

Alphabet Inc. Class A	Communication Services
Amazon.com, Inc.	Consumer Discretionary
CME Group Inc. Class A	Financials
Meta Platforms Inc Class A	Communication Services
Microsoft Corporation	Information Technology
Netflix, Inc.	Communication Services
Schneider Electric SE	Industrials
Sony Group Corporation	Consumer Discretionary
Tencent Holdings Ltd	Communication Services
Vertex Pharmaceuticals Incorporated	Health Care

**SECTOR BREAKDOWN**

Consumer Discretionary	9.5%
Consumer Staples	1.9%
Energy	1.9%
Financials	9.3%
Health Care	19.3%
Industrials	14.6%
Information Technology	22.7%
Materials	1.1%
Real Estate	1.1%
Communication Services	14.9%
Cash	3.5%

**CAPITALISATION BREAKDOWN**

Under 5bn USD	0.8%
In between 5bn - 10bn USD	2%
In between 10bn - 50bn USD	17.6%
In between 50bn - 150bn USD	27.7%
In between 150bn - 500bn USD	27.7%
Above 500bn USD	20.7%
Cash	3.5%

**REGION BREAKDOWN**

North America	57.9%
Europe ex-UK	16.6%
Emerging Markets	8.4%
Japan	5.9%
UK	5.2%
Asia Pacific ex-Japan	2.6%
Cash	3.5%

**STATISTICAL DATA**

VOLATILITY<sup>8</sup> 11%

NUMBER OF STOCKS 60

BETA<sup>9</sup> 0.9

## APRIL REPORT

### COMMENTARY

#### Summary

- The Fund returned -1.0% in April, declining less than the benchmark, which fell -1.7%, supported by strength in Healthcare and Communication Services.
- Global equities were mixed. The US market sold off sharply following sweeping tariff announcements, while most other regions rose after the administration paused the rollout of reciprocal tariffs. Consumer Staples and Utilities outperformed, while Energy lagged.
- **Johnson & Johnson** was added to the portfolio during the month. **Chugai Pharmaceutical** was a key contributor following positive GLP-1 trial results, while **UnitedHealth** and **Thermo Fisher Scientific**.

#### Market Commentary

Global equity markets were mixed in April, shaped by sharp volatility early in the month following the announcement of sweeping US trade tariffs. The proposed measures included a 10% baseline tariff on all imported goods, alongside potential reciprocal tariffs targeting specific countries. The US market reacted swiftly, falling nearly 12% at its lowest point, as investors assessed the implications for global supply chains and inflation.

Sentiment improved later in the month after the administration postponed most of the reciprocal tariffs for 90 days, with the exception of those directed at China. This partial reversal helped stabilise global markets, with most major regions finishing higher. Japan advanced more than 5%, supported by improved investor confidence. Mexico posted strong gains as certain exports were granted exemptions under the US-Mexico-Canada Agreement. Emerging Markets rose modestly, though gains were tempered by weakness in Chinese equities after the announcement of a 145% tariff on imports from China.

At a sector level, defensive areas of the market outperformed. Consumer Staples and Utilities saw renewed interest amid heightened uncertainty, while Energy declined sharply, reflecting global growth concerns and weaker oil prices.

#### Portfolio Commentary

The Fund returned -0.97% in April, holding up better than broader equity markets despite a challenging backdrop for global markets. Gains in select Healthcare and Communication Services holdings helped offset weakness elsewhere, while the portfolio's limited exposure to highly tariff-sensitive names was beneficial.

**Chugai Pharmaceutical** was a notable contributor. Shares in the Japan-based biopharmaceutical firm rose after its partner Eli Lilly announced encouraging Phase 3 results for Orforglipron, an oral GLP-1 treatment for diabetes and weight management. The drug's strong efficacy and tolerability profile significantly enhanced its commercial potential, lifting sentiment around Chugai's role in the growing GLP-1 space.

**Netflix** contributed positively. The US-based streaming company delivered better-than-expected first-quarter results and reported steady subscriber growth despite a more uncertain macro environment. The Fund also benefited from not holding **Apple**, which declined due to renewed concerns around its exposure to Chinese manufacturing following the announcement of increased US import tariffs.

On the downside, **UnitedHealth Group** detracted from performance. The health insurer reported a higher-than-anticipated medical loss ratio, which raised short-term profitability concerns. **Thermo Fisher Scientific** also underperformed as investors reassessed near-term growth expectations given reduced biotech sector funding.

The Fund initiated a new position in **Johnson & Johnson** during the month. The US-based healthcare leader has a long history of successfully identifying early-stage blockbuster drugs and benefits from strong positions across both pharmaceuticals and medical devices. The company's scale and disciplined approach to R&D and acquisitions support a durable growth profile. The investment team viewed the recent share price as an attractive entry point for a high-quality, diversified healthcare business.

The Fund remains focused on building a portfolio of high-quality companies with resilient earnings profiles and sustainable growth drivers. The current environment continues to highlight the importance of a research-driven approach that emphasises business quality, industry structure, and sustainable profitability.

FEATURES	
APIR CODE	PCL0026AU
REDEMPTION PRICE	A\$ 1.114
FEES *	Management Fee: 0.974% Performance Fee: Nil
MINIMUM INITIAL INVESTMENT	\$10,000
FUM AT MONTH END	A\$ 31.35m
STRATEGY INCEPTION DATE	1 December 1989
BENCHMARK	MSCI All Country World Total Return Index (net) in \$A

## FUND MANAGERS



**Jingyi Li**  
Portfolio Manager



**Rick Schmidt**  
Portfolio Manager

1. Harding Loevner was appointed fund manager as of 10 May 2021. June 2021 represents the first full month of Harding Loevner managing the Fund.
  2. Class B Inception date 1 July 2015. Figures shown are calculated from the continuous performance of both the current and previous strategies. For performance see row labelled Fund (APIR PCL0026AU) in the table above which is the continuous performance of both the current and previous (shaded) strategies.
  3. Harding Loevner Global Equity Strategy inception 1 Dec 1989
  4. Prior to June 2021, the Harding Loevner Global Equity Strategy performance (labelled 'Current Strategy (Partial Simulation)' and shown in the shaded area) includes the strategy performance simulated by Pengana from the monthly gross returns of the Harding Loevner Global Equity strategy. This simulation was done by: 1) the conversion of US-denominated gross returns to AUD, 2) applying the fee structure of Class B. From June 2021 the strategy performance is the performance of the Pengana Harding Loevner International Fund Class B.
  5. MSCI All Country World Total Return Index in AUD.
  6. Performance for periods greater than 12 months are annualised. Net performance figures are shown after all fees and expenses and assume reinvestment of distributions. No allowance has been made for buy/sell spreads. Please refer to the PDS for information regarding risks. Past performance is not a reliable indicator of future performance, the value of investments can go up and down.
  7. The Harding Loevner Global Equity Strategy performance (shown in the shaded area in the chart, and in the performance table as row labeled 'Harding Loevner Global Equity Strategy') has been simulated by Pengana from the monthly gross returns of the Harding Loevner Global Equity strategy. This simulation was done by: 1) the conversion of US-denominated gross returns to AUD, 2) applying the fee structure of the stated class. Strategy Inception 30 November 1989.
  8. Annualised standard deviation since inception.
  9. Relative to MSCI All Country World Total Return Index in AUD
- \* For further information regarding fees please see the PDS available on our website.

## PENGANA HARDING LOEVNER INTERNATIONAL FUND

### PENGANA CAPITAL LIMITED

ABN 30 103 800 568  
AFSL 226566

### CLIENT SERVICE

T: +61 2 8524 9900  
F: +61 2 8524 9901  
E: [clientservice@pengana.com](mailto:clientservice@pengana.com)



### PENGANA.COM

Pengana Capital Ltd (ABN 30 103 800 568, Australian financial services licence number 226566) is the issuer of units in the Pengana Harding Loevner International Fund (ARSN 610 351 641) (the "Fund"). A Product Disclosure Statement (PDS) and Target Market Determination are available and can be obtained from our distribution team or website. A person should obtain a copy of the Product Disclosure Statement and should consider the Product Disclosure Statement carefully before deciding whether to acquire, or to continue to hold, or making any other decision in respect of, the units in the Fund. This report was prepared by Pengana Capital Ltd and does not contain any investment recommendation or investment advice. This report has been prepared without taking account of any person's objectives, financial situation or needs. Therefore, before acting on any information contained within this report a person should consider the appropriateness of the information, having regard to their objectives, financial situation and needs. Neither Pengana Capital Ltd nor its related entities, directors or officers guarantees the performance of, or the repayment of capital or income invested in, the Fund. An investment in the Fund is subject to investment risk including a possible delay in repayment and loss of income and principal invested.